T
TAYSHA GENE THERAPIES INC
NASDAQ: TSHA (Taysha Gene Therapies, Inc.)
最近更新时间: 26分钟之前6.67
-0.18 (-2.63%)
| 前收盘价格 | 6.85 |
| 收盘价格 | 6.75 |
| 成交量 | 3,277,204 |
| 平均成交量 (3个月) | 2,796,144 |
| 市值 | 1,916,698,112 |
| 价格/销量 (P/S) | 314.29 |
| 股市价格/股市净资产 (P/B) | 9.25 |
| 52周波幅 | |
| 利润日期 | 6 May 2026 |
| 营业利益率 (TTM) | -930.54% |
| 稀释每股收益 (EPS TTM) | -0.340 |
| 季度收入增长率 (YOY) | -32.50% |
| 总债务/股东权益 (D/E MRQ) | 111.93% |
| 流动比率 (MRQ) | 5.35 |
| 营业现金流 (OCF TTM) | -83.45 M |
| 杠杆自由现金流 (LFCF TTM) | -52.28 M |
| 资产报酬率 (ROA TTM) | -35.91% |
| 股东权益报酬率 (ROE TTM) | -159.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Taysha Gene Therapies, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 12.11% |
| 机构持股比例 | 67.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ra Capital Management, L.P. | 31 Dec 2025 | 23,555,648 |
| Avoro Capital Advisors Llc | 31 Dec 2025 | 21,700,000 |
| Rtw Investments, Lp | 31 Dec 2025 | 16,398,297 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 13,750,000 |
| Siren, L.L.C. | 31 Dec 2025 | 10,129,913 |
| Octagon Capital Advisors Lp | 31 Dec 2025 | 8,859,911 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 7,931,403 |
| Barclays Plc | 31 Dec 2025 | 5,539,001 |
| 52周波幅 | ||
| 中 | 10.00 (49.93%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 03 Mar 2026 | 10.00 (49.93%) | 购买 | 4.53 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合